LENZ Therapeutics (LENZ) Gains from Sales and Divestitures (2021 - 2023)
LENZ Therapeutics (LENZ) reported Gains from Sales and Divestitures of $751758.0 for Q4 2023, up 35.83% year-over-year from $553443.0 in Q4 2022, and up 6.93% on a QoQ basis from $703035.0 in Q3 2023.
LENZ Therapeutics (LENZ) has 3 years of Gains from Sales and Divestitures data on file, last reported at $751758.0 in Q4 2023.
- Quarterly Gains from Sales and Divestitures rose 35.83% year-over-year to $751758.0 in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $751758.0 (up 35.83% YoY) and the FY2023 annual result came in at $751758.0, up 35.83% from the prior year.
- Gains from Sales and Divestitures rose to $751758.0 in Q4 2023 per LENZ's latest filing, from $703035.0 in the prior quarter.
- Across five years, Gains from Sales and Divestitures topped out at $751758.0 in Q4 2023 and bottomed at $241842.0 in Q2 2021.
- The 3-year median for Gains from Sales and Divestitures is $502152.0 (2022), against an average of $499902.0.
- The widest annual swing landed in 2022, when Gains from Sales and Divestitures surged 86.11%; it then jumped 35.83% in 2023.
- Tracing LENZ's Gains from Sales and Divestitures over 3 years: stood at $345966.0 in 2021, then jumped by 59.97% to $553443.0 in 2022, then jumped by 35.83% to $751758.0 in 2023.
- Per Business Quant, the three latest LENZ Gains from Sales and Divestitures figures stand at $751758.0 (Q4 2023), $703035.0 (Q3 2023), and $653970.0 (Q2 2023).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | LENZ Therapeutics | 235.77 Mn | 235.77 Mn | 825,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 751,758.00 |
| Dec 31, 2023 | 751,758.00 |
| Sep 30, 2023 | 703,035.00 |
| Sep 30, 2023 | 703,035.00 |
| Jun 30, 2023 | 653,970.00 |
| Jun 30, 2023 | 653,970.00 |
| Mar 31, 2023 | 604,734.00 |
| Mar 31, 2023 | 604,734.00 |
| Dec 31, 2022 | 553,443.00 |
| Dec 31, 2022 | 553,443.00 |
| Sep 30, 2022 | 502,152.00 |
| Sep 30, 2022 | 502,152.00 |
| Jun 30, 2022 | 450,090.00 |
| Jun 30, 2022 | 450,090.00 |
| Mar 31, 2022 | 398,028.00 |
| Mar 31, 2022 | 398,028.00 |
| Dec 31, 2021 | 345,966.00 |
| Dec 31, 2021 | 345,966.00 |
| Sep 30, 2021 | 293,904.00 |
| Sep 30, 2021 | 293,904.00 |
| Jun 30, 2021 | 241,842.00 |
| Jun 30, 2021 | 241,842.00 |